Posted by Michael Wonder on 03 Nov 2025
Viridian Therapeutics announces successful October submission of biologics license application to US FDA for veligrotug in thyroid eye disease
3 November 2025 - Viridian Therapeutics today announced the successful October submission of its biologics license application to the US FDA for veligrotug, the company’s investigational therapy for the treatment of thyroid eye disease.
The biologics license application submission is supported by data from two pivotal phase 3 clinical trials, THRIVE and THRIVE-2, evaluating the efficacy and safety of veligrotug in patients with active and chronic thyroid eye disease, respectively.
